Biology and Innovative Therapeutics of Locally Aggressive Cancers Unit EA

Caen, France

Biology and Innovative Therapeutics of Locally Aggressive Cancers Unit EA

Caen, France

Time filter

Source Type

Jebahi A.,Normandy University | Jebahi A.,Biology and Innovative Therapeutics of Locally Aggressive Cancers Unit EA | Jebahi A.,Francois Baclesse Comprehensive Cancer Center | Villedieu M.,Normandy University | And 31 more authors.
Cancer Letters | Year: 2014

We previously showed that Bcl-xL and Mcl-1 cooperatively protect platinum-resistant ovarian cancer cells from apoptosis. Here we assessed the anticancer potential of combining ABT-737-induced inhibition of Bcl-xL with Mcl-1 inhibition via PI3K/Akt/mTOR pathway disruption using NVP-BEZ235. NVP-BEZ235 inhibited cell proliferation without inducing apoptosis. It strongly repressed Mcl-1 expression and induced Puma expression in both cell lines tested while differentially modulating Bim between the two. Interestingly, NVP-BEZ235 efficiently sensitized ovarian carcinoma cells to ABT-737, provided that Bim expression was induced. Moreover, inhibiting the ERK1/2 pathway restored Bim expression and sensitized low Bim-expressing cancer cells to the BEZ235/ABT-737 treatment. © 2014 The Authors.

Loading Biology and Innovative Therapeutics of Locally Aggressive Cancers Unit EA collaborators
Loading Biology and Innovative Therapeutics of Locally Aggressive Cancers Unit EA collaborators